Published in PLoS Pathog on October 02, 2014
Male Circumcision for HIV Prevention in Rakai, Uganda | NCT00425984
Non-Cationic Proteins Are Associated with HIV Neutralizing Activity in Genital Secretions of Female Sex Workers. PLoS One (2015) 1.43
Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol (2015) 1.03
Molecular Signatures of Immune Activation and Epithelial Barrier Remodeling Are Enhanced during the Luteal Phase of the Menstrual Cycle: Implications for HIV Susceptibility. J Virol (2015) 0.96
Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr Opin HIV AIDS (2015) 0.87
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
The role of Fc receptors in HIV prevention and therapy. Immunol Rev (2015) 0.81
Defensins at the Mucosal Surface: Latest Insights into Defensin-Virus Interactions. J Virol (2016) 0.79
The gut microbiome in human immunodeficiency virus infection. BMC Med (2016) 0.78
The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention. Mucosal Immunol (2016) 0.77
In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol (2015) 0.77
HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. J Virol (2016) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS (2017) 0.75
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS (2008) 2.67
HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol (2006) 2.10
Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med (2004) 2.05
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS (2009) 1.64
Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol (2008) 1.52
Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol (2004) 1.50
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A (2012) 1.50
The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res (2007) 1.50
HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (2009) 1.49
Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest (2005) 1.47
Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun (2005) 1.41
Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa. J Acquir Immune Defic Syndr (2006) 1.36
HIV-1 transmission in the male genital tract. Am J Reprod Immunol (2010) 1.35
alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS (2003) 1.34
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol (2008) 1.22
Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS (2009) 1.21
Immunobiology of the human penile urethra. Am J Pathol (1995) 1.20
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis (2001) 1.20
Langerhans' cell density and degree of keratinization in foreskins of Chinese preschool boys and adults. Int Urol Nephrol (2009) 1.17
Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol (2010) 1.17
Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood (2007) 1.16
Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS (2013) 1.13
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS (2002) 1.09
HIV-1 efficient entry in inner foreskin is mediated by elevated CCL5/RANTES that recruits T cells and fuels conjugate formation with Langerhans cells. PLoS Pathog (2011) 1.07
HIV infection and immune defense of the penis. Am J Reprod Immunol (2011) 1.06
Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses (2010) 1.05
Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses (2009) 1.03
Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS (2002) 1.01
The role of the foreskin in male circumcision: an evidence-based review. Am J Reprod Immunol (2010) 1.01
Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol (2000) 0.99
Immunology of the human genital tract. Curr Opin Infect Dis (2003) 0.99
Antimicrobial peptide microbicides targeting HIV. Protein Pept Lett (2005) 0.96
Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS (2009) 0.95
Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS (2007) 0.94
Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders. Sex Transm Infect (2011) 0.91
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology (2003) 0.90
Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. AIDS Res Hum Retroviruses (2000) 0.90
Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin. AIDS (2012) 0.89
Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS (2008) 0.87
Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol (2013) 0.84
Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. AIDS (2008) 0.84
Innate and acquired immunity in the human penile urethra. J Reprod Immunol (2011) 0.82
Foreskin length in uncircumcised men is associated with subpreputial wetness. Int J STD AIDS (2008) 0.82
Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients. Scand J Infect Dis (2004) 0.80
The role of viral introductions in sustaining community-based HIV epidemics in rural Uganda: evidence from spatial clustering, phylogenetics, and egocentric transmission models. PLoS Med (2014) 1.43
Schistosoma mansoni Infection in Ugandan Men Is Associated with Increased Abundance and Function of HIV Target Cells in Blood, but Not the Foreskin: A Cross-sectional Study. PLoS Negl Trop Dis (2015) 0.75
Chemokine Levels in the Penile Coronal Sulcus Correlate with HIV-1 Acquisition and Are Reduced by Male Circumcision in Rakai, Uganda. PLoS Pathog (2016) 0.75
Cross-sectional comparative study of risky sexual behaviours among HIV-infected persons initiated and waiting to start antiretroviral therapy in rural Rakai, Uganda. BMJ Open (2017) 0.75
HIV self-testing values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: A qualitative study. PLoS One (2017) 0.75
Efficacy of knowledge and competence-based training of non-physicians in the provision of early infant male circumcision using the Mogen clamp in Rakai, Uganda. BJU Int (2016) 0.75
Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis (2017) 0.75
HIV serologically indeterminate individuals: Future HIV status and risk factors. PLoS One (2020) 0.75